Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients
Epilepsy, Epilepsies, Partial, Epilepsy, Generalized
About this trial
This is an interventional treatment trial for Epilepsy focused on measuring Epilepsy, Partial Epilepsy, Secondary Generalized Epilepsy, Primary Generalized Epilepsy, Tonic-Clonic Seizures, Topiramate, Weight Loss
Eligibility Criteria
Inclusion Criteria: A diagnosis of partial onset epilepsy, with or without secondary generalization. Patients with a diagnosis of epilepsy characterized by primary generalized tonic-clonic seizures may also qualify Currently taking one or more anti-epileptic medications on a stable dose for one month Weight between 40 and 130 kg (88 to 286 lbs) Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing an acceptable method of contraception (requires negative pregnancy test). Exclusion Criteria: Patients with rapidly progressive disorders that may impair their weight or their reliable participation in the study Patients prone to severe malabsorption and/or metabolic disorders Patients who have mental retardation or impairment which would confound the interpretation of this study History (within the past six months) of a psychiatric or mood disorder requiring medical treatment History of poor compliance with past anti-epileptic drug therapy Suicide attempt in the past five years